Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wuhan YZY Biopharma Co., Ltd. Class H ( (HK:2496) ) just unveiled an announcement.
Wuhan YZY Biopharma Co., Ltd. announced a change in its supervisory committee with the resignation of Mr. Zhang Jing as an employee representative supervisor due to personal career development reasons. Dr. Wang Tao has been appointed as the new employee representative supervisor, bringing over 18 years of experience in the research and development of antibody and protein drugs. This change is expected to strengthen the company’s research and development capabilities, potentially enhancing its industry positioning and operational effectiveness.
The most recent analyst rating on (HK:2496) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Wuhan YZY Biopharma Co., Ltd. Class H stock, see the HK:2496 Stock Forecast page.
More about Wuhan YZY Biopharma Co., Ltd. Class H
Wuhan YZY Biopharma Co., Ltd. is a pharmaceutical company based in China, focusing on the research and development of antibody and protein drugs. The company operates within the pharmaceutical industry and is involved in innovative drug development, aiming to address various medical needs.
Average Trading Volume: 2,930
Technical Sentiment Signal: Hold
See more insights into 2496 stock on TipRanks’ Stock Analysis page.